ClinicaliQ Trial Snapshot
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma — Recruiting • Phase III • Oncology • NCT07562152.
- What is being tested: Atebimetinib (a MEK inhibitor) combined with modified gemcitabine-nab-paclitaxel (GnP) chemotherapy versus standard-of-care GnP alone as first-line treatment for metastatic pancreatic adenocarcinoma.
- Patient eligibility: Adults with newly diagnosed metastatic pancreatic adenocarcinoma who are treatment-Phase IIIïve and have adequate organ function; this represents the population with the poorest prognosis and greatest clinical need.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Eligibility Snapshot
- : * Must be ≥18 years of age * Must have confirmed diagnosis according to AJCC staging as follows: * Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Participants must be treatment naive as follows: * First-line PDAC participants will have received no previous systemic anti-cancer therapy * Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria * Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.